Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The Neuroepithelium Disruption Could Generate Autoantibodies against AQP4 and Cause Neuromyelitis Optica and Hydrocephalus.
Structural mechanism for statin inhibition of HMG-CoA reductase.
The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?
Young Researchers in Life Sciences Meeting 2012
Do not treat from CIS onset: evaluate disease course and prognosis first - No (treat!).
Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.
A Large-Scale Study of Anxiety and Depression in People with Multiple Sclerosis: A Survey via the Web Portal of the UK MS Register.
Harnessing monocyte-derived macrophages to control central nervous system pathologies: No longer 'if' but 'how'
Immunotherapy of Multiple Sclerosis : The State of the Art.
Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis.
Dark microglia: A new phenotype predominantly associated with pathological states.
Quantitative Evaluation of BAFF, HMGB1, TLR 4 AND TLR 7 Expression in Patients with Relapsing Remitting Multiple Sclerosis.
Alemtuzumab 3-year data show durable effect on MS disability
Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome.
Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy.
Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. A new entity?
Fingolimod for multiple sclerosis: a review for the specialist nurse.
Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system.
White matter volume is decreased in the brain of patients with neuromyelitis optica.
The gut microbiome in multiple sclerosis.
ACUTE RETINAL NECROSIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A NATALIZUMAB-TREATED PATIENT WITH MULTIPLE SCLEROSIS.
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
The occurrence of dystonia in upper-limb multiple sclerosis tremor.
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.

Pages